News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
755,706 Results
Type
Article (45511)
Company Profile (330)
Press Release (709849)
Multimedia
Podcasts (120)
Webinars (22)
Section
Business (212478)
Career Advice (2117)
Deals (36544)
Drug Delivery (129)
Drug Development (82717)
Employer Resources (177)
FDA (17034)
Job Trends (15431)
News (357647)
Policy (33636)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2738)
Accelerated approval (42)
Adcomms (25)
Allergies (165)
Alliances (52622)
ALS (195)
Alzheimer's disease (1769)
Antibody-drug conjugate (ADC) (381)
Approvals (17344)
Artificial intelligence (645)
Autoimmune disease (228)
Automation (52)
Bankruptcy (367)
Best Places to Work (11930)
BIOSECURE Act (20)
Biosimilars (204)
Biotechnology (220)
Bladder cancer (179)
Brain cancer (64)
Breast cancer (695)
Cancer (5387)
Cardiovascular disease (450)
Career advice (1797)
Career pathing (40)
CAR-T (312)
CDC (55)
Celiac Disease (2)
Cell therapy (831)
Cervical cancer (41)
Clinical research (71069)
Collaboration (1978)
Company closure (5)
Compensation (1285)
Complete response letters (70)
COVID-19 (2812)
CRISPR (106)
C-suite (1010)
Cystic fibrosis (154)
Data (7116)
Decentralized trials (3)
Denatured (44)
Depression (155)
Dermatology (58)
Diabetes (554)
Diagnostics (7111)
Digital health (54)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (310)
Drug pricing (197)
Drug shortages (31)
Duchenne muscular dystrophy (272)
Earnings (92772)
Editorial (61)
Employer branding (22)
Employer resources (157)
Events (123268)
Executive appointments (1068)
FDA (20515)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1671)
Gene editing (226)
Generative AI (58)
Gene therapy (687)
GLP-1 (1036)
Government (4801)
Grass and pollen (7)
Guidances (398)
Healthcare (19643)
HIV (77)
Huntington's disease (52)
IgA nephropathy (91)
Immunology and inflammation (276)
Immuno-oncology (82)
Indications (158)
Infectious disease (3132)
Inflammatory bowel disease (207)
Inflation Reduction Act (14)
Influenza (132)
Intellectual property (281)
Interviews (328)
IPO (16997)
IRA (51)
Job creations (3835)
Job search strategy (1501)
JPM (62)
Kidney cancer (18)
Labor market (93)
Layoffs (569)
Leadership (36)
Legal (8175)
Liver cancer (100)
Longevity (28)
Lung cancer (717)
Lymphoma (409)
Machine learning (54)
Management (63)
Manufacturing (944)
MASH (177)
Medical device (14602)
Medtech (14683)
Mergers & acquisitions (20717)
Metabolic disorders (1423)
mRNA (196)
Multiple sclerosis (172)
NASH (17)
Neurodegenerative disease (390)
Neuropsychiatric disorders (97)
Neuroscience (3179)
Neurotech (1)
NextGen: Class of 2026 (6855)
Non-profit (4663)
Now hiring (73)
Obesity (667)
Opinion (289)
Ovarian cancer (186)
Pain (229)
Pancreatic cancer (258)
Parkinson's disease (343)
Partnered (34)
Patents (568)
Patient recruitment (603)
Peanut (63)
People (61529)
Pharmaceutical (67)
Pharmacy benefit managers (32)
Phase 1 (22312)
Phase 2 (31262)
Phase 3 (23191)
Pipeline (7187)
Policy (312)
Postmarket research (2584)
Preclinical (9546)
Press Release (71)
Prostate cancer (278)
Psychedelics (49)
Radiopharmaceuticals (323)
Rare diseases (1006)
Real estate (6288)
Recruiting (70)
Regulatory (25610)
Reports (54)
Research institute (2547)
Resumes & cover letters (365)
Rett syndrome (32)
RNA editing (20)
RSV (86)
Schizophrenia (166)
Series A (281)
Series B (204)
Service/supplier (14)
Sickle cell disease (108)
Special edition (22)
Spinal muscular atrophy (165)
Sponsored (46)
Startups (3892)
State (2)
Stomach cancer (18)
Supply chain (118)
Tariffs (85)
The Weekly (73)
Vaccines (1101)
Venture capital (104)
Weight loss (427)
Women's health (112)
Worklife (19)
Date
Last 7 days (651)
Last 30 days (2491)
Last 365 days (30642)
2026 (8183)
2025 (30957)
2024 (36211)
2023 (41135)
2022 (52398)
2021 (56994)
2020 (55612)
2019 (48407)
2018 (36442)
2017 (33541)
2016 (33139)
2015 (39358)
2014 (32941)
2013 (27985)
2012 (30242)
2011 (30847)
2010 (28813)
Location
Africa (779)
Alabama (93)
Alaska (7)
Arizona (342)
Arkansas (15)
Asia (42186)
Australia (7010)
California (12476)
Canada (3533)
China (1258)
Colorado (533)
Connecticut (535)
Delaware (378)
Europe (92801)
Florida (1861)
Georgia (407)
Hawaii (3)
Idaho (65)
Illinois (987)
India (81)
Indiana (569)
Iowa (23)
Japan (497)
Kansas (133)
Kentucky (47)
Louisiana (40)
Maine (73)
Maryland (1502)
Massachusetts (9017)
Michigan (374)
Minnesota (695)
Mississippi (7)
Missouri (149)
Montana (36)
Nebraska (29)
Nevada (139)
New Hampshire (89)
New Jersey (3325)
New Mexico (30)
New York (3285)
North Carolina (1604)
North Dakota (10)
Northern California (6139)
Ohio (376)
Oklahoma (24)
Oregon (44)
Pennsylvania (2512)
Puerto Rico (27)
Rhode Island (51)
South America (1169)
South Carolina (77)
South Dakota (1)
Southern California (4908)
Tennessee (203)
Texas (1972)
United States (44393)
Utah (376)
Vermont (1)
Virginia (298)
Washington D.C. (81)
Washington State (1009)
West Virginia (4)
Wisconsin (130)
Wyoming (2)
755,706 Results for "prolias technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
December 23, 2025
·
6 min read
Press Releases
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
November 24, 2025
·
7 min read
Press Releases
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
November 26, 2025
·
6 min read
Press Releases
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
September 23, 2025
·
9 min read
Press Releases
Hubly Surgical awarded Breakthrough Technology Designation for Neurosurgical Products with Premier, Inc.
March 3, 2026
·
2 min read
Press Releases
Quanta System Inc.: Strengthening the U.S. Presence of Italian Laser Technology
March 1, 2026
·
4 min read
Press Releases
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
September 19, 2025
·
9 min read
Press Releases
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
March 12, 2026
·
5 min read
Press Releases
DW Healthcare Partners Announces Sale of LKC Technologies to AMETEK, Inc.
February 3, 2026
·
2 min read
Press Releases
Medical Care Technologies Inc. (OTC PINK:MDCE) Reports 63% Revenue Growth, Strong Profitability, and Significant Cash Flow Improvement in 2025
March 26, 2026
·
3 min read
1 of 75,571
Next
